Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19
Open Access
- 2 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Signal Transduction and Targeted Therapy
- Vol. 5 (1), 1-6
- https://doi.org/10.1038/s41392-020-00301-9
Abstract
COVID-19 patients exhibit differential disease severity after SARS-CoV-2 infection. It is currently unknown as to the correlation between the magnitude of neutralizing antibody (NAb) responses and the disease severity in COVID-19 patients. In a cohort of 59 recovered patients with disease severity including severe, moderate, mild, and asymptomatic, we observed the positive correlation between serum neutralizing capacity and disease severity, in particular, the highest NAb capacity in sera from the patients with severe disease, while a lack of ability of asymptomatic patients to mount competent NAbs. Furthermore, the compositions of NAb subtypes were also different between recovered patients with severe symptoms and with mild-to-moderate symptoms. These results reveal the tremendous heterogeneity of SARS-CoV-2-specific NAb responses and their correlations to disease severity, highlighting the needs of future vaccination in COVID-19 patients recovered from asymptomatic or mild illness.Keywords
Funding Information
- the National Natural Science Fund for Distinguished Young Scholars
This publication has 36 references indexed in Scilit:
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implicationsPublished by Cold Spring Harbor Laboratory ,2020
- Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoVNature Communications, 2020
- Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2Science, 2020
- Cryo-EM structure of the 2019-nCoV spike in the prefusion conformationScience, 2020
- Characterization of spike glycoprotein of 2019-nCoV on virus entry and its immune cross-reactivity with spike glycoprotein of SARS-CoVPublished by Research Square Platform LLC ,2020
- Anti–spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infectionJCI Insight, 2019
- Pre-fusion structure of a human coronavirus spike proteinNature, 2016
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009